Last reviewed · How we verify
SR-T100 gel with 2.3% SM
At a glance
| Generic name | SR-T100 gel with 2.3% SM |
|---|---|
| Sponsor | G&E Herbal Biotechnology Co., LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients (PHASE2)
- Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) (PHASE2)
- Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis (PHASE2)
- SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR-T100 gel with 2.3% SM CI brief — competitive landscape report
- SR-T100 gel with 2.3% SM updates RSS · CI watch RSS
- G&E Herbal Biotechnology Co., LTD portfolio CI